Will 21st Century Cures Act benefit hospitals?

First: The Globe is getting some attention for its five-part narrative about a family that helped  start a drug company to keep their son on an experimental cancer treatment. Nicely written narrative with illustrations and audio. We won't give away the ending.  Also, here's what people were saying a year ago about the "21st Century … Continue reading Will 21st Century Cures Act benefit hospitals?

Advertisements

Two Boston meetings look at the role of patient advocates. They offer two very different perspectives.

Pharmaceutical manufacturers often  look to patient advocates for help winning approval for new drugs. Their most recent success in this area was the FDA’s approval of a new drug for Duchenne muscular dystrophy. That decision came despite recommendations against approval from FDA staff. In an editorial, the Boston Globe questioned the FDA’s move while noting … Continue reading Two Boston meetings look at the role of patient advocates. They offer two very different perspectives.

April 26: Boston health news round up

Health writers on both ends of 135 Morrissey Boulevard have been busy -- main Globe newsroom to STAT down the hall:  From Stat;  from the Globe business desk.  Stat shared this story with the print edition of Globe today: Lam, a 22-year-old aspiring doctor, is part of the fast-growing industry of medical scribes working in hospitals … Continue reading April 26: Boston health news round up

Is female Viagra a scam? Boston women’s health group questions drug, supporters

The non-profits pressuring the FDA to approve a drug billed as female Viagra do not quite make up a top ten list or women's health advocacy organizations. This health writer has never heard of most of the groups cited in Sunday's New York Times story. But familiar women's health groups, like Boston's Our Bodies, Ourselves, … Continue reading Is female Viagra a scam? Boston women’s health group questions drug, supporters

Should the FDA approve Vertex’s new cystic fibrosis drug?

The scene at the FDA hearing was familiar. All the  advisory committees have seen it play out again and again. Yesterday, it was the Pulmonary-Allergy Drug committee: The pharma doc with the convincing statement. The weeping patients. The drug likely to cost a couple thousand a month offering a slim  benefit over an existing drugs. … Continue reading Should the FDA approve Vertex’s new cystic fibrosis drug?

Avandia, the Duke Clinical Research Institute and conflict of interest

The  debate over potential bias at the Duke Clinical Research Institute emerging fro  this morning's Avandia hearing inspired a trip to the archives. This story looked at many of the same issues, which came up when  the Duke clinical trials operation was young. By Tinker Ready from The Raleigh News & Observer Genentech and university … Continue reading Avandia, the Duke Clinical Research Institute and conflict of interest

Is Avandia safe? FDA to consider restrictions on the diabetes drug, local docs in the fray

Dr. Clifford J. Rosen, director of clinical and translational medicine at the Maine Medical Center in Portland,  led the advisory committee that on 2010 set strict limits on the use of the  diabetes drug Avandia after it was linked to  heart problems. The New York Times reported on Sunday on the FDA's  meeting this week, where … Continue reading Is Avandia safe? FDA to consider restrictions on the diabetes drug, local docs in the fray